BioPorto マネジメント

マネジメント基準チェック /24

BioPortoの CEO はPeter Eriksenで、 Jan2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.18%を直接所有しており、その価値は€ 167.30K 。経営陣と取締役会の平均在任期間はそれぞれ0.7年と10.8年です。

主要情報

Peter Eriksen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.2%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	10.8yrs

経営陣の近況

Recent updates

CEO報酬分析

BioPorto の収益と比較して、Peter Eriksen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-DKK 50m
Mar 31 2024	n/a	n/a	-DKK 54m
Dec 31 2023	n/a	n/a	-DKK 56m
Sep 30 2023	n/a	n/a	-DKK 70m
Jun 30 2023	n/a	n/a	-DKK 78m
Mar 31 2023	n/a	n/a	-DKK 75m
Dec 31 2022	DKK 292k	n/a	-DKK 76m
Sep 30 2022	n/a	n/a	-DKK 68m
Jun 30 2022	n/a	n/a	-DKK 62m
Mar 31 2022	n/a	n/a	-DKK 59m
Dec 31 2021	DKK 3m	n/a	-DKK 57m
Sep 30 2021	n/a	n/a	-DKK 54m
Jun 30 2021	n/a	n/a	-DKK 60m
Mar 31 2021	n/a	n/a	-DKK 62m
Dec 31 2020	DKK 7m	DKK 3m	-DKK 62m
Sep 30 2020	n/a	n/a	-DKK 64m
Jun 30 2020	n/a	n/a	-DKK 68m
Mar 31 2020	n/a	n/a	-DKK 69m
Dec 31 2019	DKK 6m	DKK 3m	-DKK 70m
Sep 30 2019	n/a	n/a	-DKK 61m
Jun 30 2019	n/a	n/a	-DKK 51m
Mar 31 2019	n/a	n/a	-DKK 43m
Dec 31 2018	DKK 4m	DKK 3m	-DKK 38m
Sep 30 2018	n/a	n/a	-DKK 38m
Jun 30 2018	n/a	n/a	-DKK 36m
Mar 31 2018	n/a	n/a	-DKK 35m
Dec 31 2017	DKK 5m	DKK 3m	-DKK 32m

報酬と市場: Peterの総報酬がGerman市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Peterの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Peter Eriksen (64 yo)

less than a year

在職期間

DKK 292,000

報酬

Mr. Peter Mørch Eriksen, BBA, serves as Chief Executive Officer at BioPorto A/S. He served as a Director of BioPorto A/S since November 15, 2021 until April 30, 2024 and served as its Interim CEO from Janu...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Peter Eriksen	Chief Executive Officer	less than a year	DKK 292.00k	0.18% € 167.3k
Niels Nielsen	Executive VP & CFO	less than a year	データなし	データなし
Lars Uttenthal	Chief Scientific Officer	no data	データなし	データなし
Gry Larsen	Executive VP & Chief Legal Officer	less than a year	データなし	データなし
Jennifer Zonderman	SVP of Global Marketing & US Commercialization	5.5yrs	データなし	データなし
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	1.9yrs	データなし	データなし
Jeffrey Haas	President & CEO of BioPorto Inc.	less than a year	データなし	データなし

0.7yrs

平均在職期間

経験豊富な経営陣: 2P4の経営陣は経験豊富とはみなされません ( 0.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Donnie Hardison	Independent Vice Chairman of the Board	3.6yrs	DKK 795.00k	0.0046% € 4.3k
John McDonough	Independent Chairman of the Board	3.6yrs	DKK 1.08m	0.095% € 88.7k
Claudio Ronco	Member of Scientific Advisory Board	10.8yrs	データなし	データなし
Mats Thoren	Director	no data	データなし	データなし
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	10.8yrs	データなし	データなし
Henrik Juuel	Director	no data	データなし	データなし
Ninfa Saunders	Independent Director	1.6yrs	DKK 458.00k	データなし
Michael Singer	Independent Director	5.3yrs	DKK 674.00k	データなし
Andrew Lewington	Vice Chairman of Scientific Advisory Board	10.8yrs	データなし	データなし
Laurent Jacob	Member of Scientific Advisory Board	10.8yrs	データなし	データなし
Michael Haase	Member of Scientific Advisory Board	10.8yrs	データなし	データなし
Hilde Geus	Member of Scientific Advisory Board	10.8yrs	データなし	データなし

10.8yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: 2P4の取締役会は経験豊富で経験豊富です ( 10.8年の平均在任期間)。

BioPorto マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Recent updates

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

Second quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.058 loss in 2Q 2023)

Bioporto A/S Affirms Earnings Guidance for 2024

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

Full year 2023 earnings released: kr.0.16 loss per share (vs kr.0.24 loss in FY 2022)

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

New major risk - Share price stability

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings released: kr.0.06 loss per share (vs kr.0.05 loss in 2Q 2022)

BioPorto A/S Maintains Earnings Guidance for the Year 2023

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings released: kr.0.05 loss per share (vs kr.0.06 loss in 1Q 2022)

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings released: kr.0.24 loss per share (vs kr.0.21 loss in FY 2021)

BioPorto A/S to Report Q1, 2023 Results on May 10, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

Third quarter 2022 earnings released

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Less than half of directors are independent

Full year 2021 earnings released: kr.0.21 loss per share (vs kr.0.30 loss in FY 2020)

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

New 90-day high: €0.66

Revenue misses expectations

Third quarter 2020 earnings released: kr.0.09 loss per share

BioPorto A/S, Annual General Meeting, Apr 29, 2021

BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 106.632762 million.

BioPorto A/S Plans Initial Clinical Evaluation of Grad-Based Test for Rapid Detection of COVID-19 Virus

New 90-day low - €0.28

Earnings released

New 90-day low - €0.30

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

マネジメント基準チェック /24